Ultrahuman has launched its M2 Live metabolic health platform in the U.S., integrating Abbott’s Lingo™ continuous glucose monitor (CGM) to offer real-time glucose data tracking.
The M2 Live platform aims to enhance access to metabolic health monitoring for health-conscious individuals, particularly those with prediabetes, without the need for a prescription. The service is positioned as a cost-effective solution, with subscription options starting at $99 per month, allowing users to stream glucose data directly into the Ultrahuman app for continuous insights.
Originally introduced in 2021, Ultrahuman's CGM-based wellness tracking has now evolved to include a comprehensive metabolic health ecosystem. M2 Live not only tracks glucose levels but also integrates data from various sources, including the Ultrahuman Ring and Blood Vision testing, to provide a holistic view of metabolic health. This data is analyzed by Jade AI, which correlates glucose fluctuations with lifestyle factors such as sleep and activity.
Ultrahuman highlights the importance of this platform amidst rising chronic health issues like Type 2 diabetes. By providing continuous metabolic insights, M2 Live aims to empower users to make informed lifestyle changes. The company also emphasizes the validation of its metabolic scoring system through clinical studies and collaborations with prestigious institutions, ensuring the reliability of its insights.